Seeing that high-grade serous ovarian cancer (HGSC) patients frequently relapse with an unfavorable response to CP-based therapy 41, 42, the association of GRP75-coupled MAM component's expression with patient's outcome were further analyzed. Here, HSPA9 is linked to ovarian serous adenocarcinoma.